omniture

Latest News

Huaneng Power International, Inc.: Announcement on Filing of Form 20-F

BEIJING, April 25, 2019 /PRNewswire/ -- Huaneng Power International, Inc. ("HPI", or the "Company")...

2019-04-26 09:26 5578

Huaneng Power International, Inc. 2019 First Quarter Net Profit Attributable to Shareholders Increased By 114.27%

BEIJING, April 25, 2019 /PRNewswire/ -- Huaneng Power International, Inc. ("HPI", or the "Company")...

2019-04-26 09:26 5610

Huaneng Power International, Inc. Power Generation Within China for the First Quarter of 2019 Decreases by 0.45% Year on Year

BEIJING, April 16, 2019 /PRNewswire/ -- Huaneng Power International, Inc. ("HPI", the "Company") (N...

2019-04-16 20:26 10146

Huaneng Power International, Inc.: RMB 0.734 Billion Net Profit Attributed to Equity Holders of the Company in 2018

BEIJING, March 19, 2019 /PRNewswire/ -- Huaneng Power International, Inc. ("HPI" or the "Company") ...

2019-03-20 01:09 6748

Long-term Strategic Cooperation Achieved between China Renaissance and LGT Bank

HONG KONG, March 14, 2019 /PRNewswire/ -- China Renaissance (Stock code: 1911.HK) and LGT Bank ente...

2019-03-14 10:30 6673

Huaneng Power International, Inc. Power Generation Within China Increased by 9.12% for the Year of 2018

BEIJING, Jan. 20, 2019 /PRNewswire/ -- Huaneng Power International, Inc. ("HPI" or the "Company") (...

2019-01-21 09:48 10511

Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-OX40 Monoclonal Antibody IBI101

SUZHOU, China, Dec. 5, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a wo...

2018-12-05 08:00 1186

Innovent Announces Global Collaboration with Hutchison MediPharma to Evaluate Combination of Sintilimab and Fruquintinib in Solid Tumors

- Global collaboration will initially evaluate Innovent's anti-PD-1 monoclonal antibody sintilimab ...

2018-11-30 08:00 1604

NMPA Accepts Biosimilar New Drug Application for IBI303, a Biosimilar Candidate to Humira(R) (adalimumab)

SUZHOU, China, Nov. 13, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 1801), a w...

2018-11-13 08:00 1711

Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with First-line Squamous NSCLC at Asia Conference on Lung Cancer 2018

SUZHOU, China, Nov. 9, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 1801), a wor...

2018-11-09 15:18 971

Huaneng Power International, Inc. 2018 Nine Months Net Profit Attributable to Shareholders Decreased by 29.33%

BEIJING, Oct. 23, 2018 /PRNewswire/ -- Huaneng Power International, Inc. ("HPI", or the "Company") ...

2018-10-23 22:07 349

Huaneng Power International, Inc. Power Generation within China Increases by 11.04% for the First Three Quarters

BEIJING, Oct. 18, 2018 /PRNewswire/ -- Huaneng Power International, Inc. ("HPI", the "Company") (NY...

2018-10-18 23:22 301

Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CTLA-4 Monoclonal Antibody

SUZHOU, China, Oct. 18, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent), a world-classChin...

2018-10-18 13:00 1247

Innovent Receives IND Approval to Initiate Clinical Trials in China with Sintilimab in Combination with its Biosimilar to Bevacizumab

SUZHOU, China, Oct. 15, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent), a world-classChin...

2018-10-15 09:25 882

Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-CD47 Monoclonal Antibody IBI-188

SUZHOU, China, Sept. 30, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent), a world-classChi...

2018-09-30 11:00 1071

First Patient Dosed in a Phase III Trial of Anti-PD-1 Antibody Sintilimab as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer

SUZHOU, China, Sept. 30, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent), a world-classChi...

2018-09-30 11:00 654

First Patient Dosed in a Phase III Trial of Anti-PD-1 Antibody Sintilimab as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer

SUZHOU, China, Sept. 29, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent), a world-classChi...

2018-09-30 11:00 501

Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-CD47 Monoclonal Antibody IBI-188

SUZHOU, China, Sept. 29, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent), a world-classChi...

2018-09-30 11:00 544

Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with Advanced Malignant Neuroendocrine Tumors at Annual Meeting of the Chinese Society of Clinical Oncology

SUZHOU, China, Sept. 21, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent), a world-classChi...

2018-09-21 10:45 880
12